NEWS. RESOURCES. DADVICE. THE HOME OF MEN-TERTAINMENT

Analysts name 2 ASX 200 healthcare shares to buy

SHARE

If you’re looking for exposure to the healthcare sector, then you may want to check out the two buy-rated shares listed below.

Here’s why analysts rate these ASX 200 healthcare shares as buys:

The first ASX 200 healthcare share that is highly rated is Pro Medicus. It is a healthcare technology company that provides industry-leading software that facilitates the clinical assessment of medical images.

The team at Bell Potter is very positive on Pro Medicus due largely to its Visage 7 product.

It commented: “Visage 7 is the fastest, most versatile viewing software on the market and it is the key reason why Pro Medicus has been successful in winning numerous high profile hospital contracts in the US, ahead of some of the largest global names in the industry.”

And while the broker acknowledges that its shares remain “expensive”, it believes the company’s “prospective EPS growth is supportive of this large premium.” Particularly given how it has “barely scratched the surface of the IDN [Integrated Delivery Network] market in the US.”

Bell Potter currently has a buy rating and $55.00 price target on the company’s shares.

Another ASX 200 healthcare share that is highly rated is ResMed. It is a sleep treatment focused medical device company with a portfolio of cloud-connected products that transform care for people with sleep apnea, COPD, and other chronic diseases.

Analysts at Morgans are very positive on the company. They currently have an add rating and $40.46 price target on its shares.

Morgans commented: “While we believe the next few quarters will likely be volatile, as Covid-related demand for ventilators continues to slow and core sleep apnoea volumes gradually lift, nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.”

Source: Read More

We’ve Already Come Too Far To End This Now.

Subscribe To Our Weekly Newsletter

Get notified about new articles